Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions

Launched by AVENTYN, INC. · May 24, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how better care coordination can improve health outcomes for patients with heart failure, acute decompensated heart failure (ADHF), and acute myocardial infarction (AMI), which is commonly known as a heart attack. The goal is to see if providing better support and resources for patients after they leave the hospital can help reduce the chances of them being readmitted. This is important because heart failure can make people feel very tired and short of breath, and those recovering from a heart attack need careful follow-up to prevent complications.

To participate in this trial, individuals must be at least 18 years old and currently hospitalized with heart failure or a heart attack. Participants will be asked to provide informed consent, meaning they will be fully informed about the study and agree to take part. The trial is currently recruiting participants, and those who join can expect to receive additional support to help manage their condition after discharge. It's also important to note that certain individuals, such as those who may not reliably attend follow-up visits, may not be eligible for the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men and women over 18 years of age are included. Eligible subjects must be hospitalized with a primary diagnosis of ADHF or acute MI. The diagnosis of HF is established by the presence of typical symptoms, signs, and objective evidence of pulmonary congestion, elevated BNP or N-terminal pro B-type natriuretic peptide (NT-pro BNP) or impaired cardiac function. Acute MI is diagnosed by presence of chest pain, arm pain, or dyspnea with elevated Troponin and/or EKG changes suggestive of Acute coronary syndrome requiring intervention or optimal medical therapy.
• Exclusion Criteria:
• • 1. Study informed consent will be obtained before enrollment in the study for Phase 1 and Phase 2
• • 2. All subjects 18 years or above will be a criteria for inclusion for Phase 1
• • 3. For Phase 2, men and women 50 years or older with positive Covid19 antigen test and one other risk factor as mentioned in the comorbid section of workflow will be enrolled in the intervention arm of the study;
• • 4. For phase 2, subjects should be able to be randomized within 48 hours of Covid19 antigen positive status
• • 5. Patients considered unreliable by the investigator concerning the requirements for follow-up visits